VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Tuesday, December 30, 2025

Stock Comparison

Copart, Inc. vs Pfizer Inc.

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

Copart, Inc.

CPRT · The NASDAQ Global Select Market

Market cap (USD)
SectorIndustrials
CountryUS
Data as of2025-12-28
Moat score
71/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Copart, Inc.'s moat claims, evidence, and risks.

View CPRT analysis

Pfizer Inc.

PFE · New York Stock Exchange

Market cap (USD)$142.1B
SectorHealthcare
CountryUS
Data as of2025-12-29
Moat score
58/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Pfizer Inc.'s moat claims, evidence, and risks.

View PFE analysis

Comparison highlights

  • Moat score gap: Copart, Inc. leads (71 / 100 vs 58 / 100 for Pfizer Inc.).
  • Segment focus: Copart, Inc. has 2 segments (83% in United States); Pfizer Inc. has 5 segments (47.4% in Primary Care).
  • Primary market structure: Oligopoly vs Oligopoly. Pricing power: n/a vs Moderate.
  • Moat breadth: Copart, Inc. has 5 moat types across 5 domains; Pfizer Inc. has 8 across 3.

Primary market context

Copart, Inc.

United States

Market

Online salvage & used vehicle remarketing services

Geography

United States

Customer

Vehicle sellers (insurance carriers, dealers, fleets) and vehicle buyers (dismantlers, rebuilders, dealers, exporters, consumers)

Role

Intermediary marketplace + ancillary services (transport, storage, title)

Revenue share

83%

Pfizer Inc.

Primary Care

Market

Branded primary care medicines and vaccines (incl. cardiovascular, migraine, pneumococcal/RSV/COVID-19)

Geography

Global

Customer

Healthcare providers, payers/PBMs, pharmacies/wholesalers, and government procurement

Role

Innovator biopharma (R&D + manufacturing + commercialization)

Revenue share

47.4%

Side-by-side metrics

Copart, Inc.
Pfizer Inc.
Ticker / Exchange
CPRT - The NASDAQ Global Select Market
PFE - New York Stock Exchange
Market cap (USD)
n/a
$142.1B
Sector
Industrials
Healthcare
HQ country
US
US
Primary segment
United States
Primary Care
Market structure
Oligopoly
Oligopoly
Market share
n/a
n/a
HHI estimate
n/a
n/a
Pricing power
n/a
Moderate
Moat score
71 / 100
58 / 100
Moat domains
Network, Supply, Demand, Legal, Financial
Legal, Demand, Supply
Last update
2025-12-28
2025-12-29

Moat coverage

Shared moat types

Compliance Advantage

Copart, Inc. strengths

Two Sided NetworkService Field NetworkData Workflow LockinBenchmark Pricing Power

Pfizer Inc. strengths

IP Choke PointProcurement InertiaGovernment Contracting RelationshipsCapex Knowhow ScaleLong Term ContractsOperational ExcellenceEmbedded R&D partnership platform

Segment mix

Copart, Inc. segments

Full profile >

United States

Oligopoly

83%

International

Competitive

17%

Pfizer Inc. segments

Full profile >

Primary Care

Oligopoly

47.4%

Specialty Care

Oligopoly

26.2%

Oncology

Competitive

24.5%

Pfizer CentreOne

Competitive

1.8%

Pfizer Ignite

Competitive

0.1%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.